



## Study the levels of adiponectin, FSH, LH and Sex hormones in Type 2 diabetes (NIDDM)

Tahreer Mohammed Natah AL-Thuwaini<sup>1</sup>, Moshtak Abdul- Adheem Wtw<sup>2</sup>, Haider Kamil Al-Saadi<sup>1</sup>, Ali Hmood Al-Saadi<sup>1</sup> and Hadeel Fadhil Farhood<sup>2</sup>

<sup>1</sup>College of Science, Babylon University.

<sup>2</sup>Medical College, Babylon University.

### ARTICLE INFO

#### Article history:

Received: 10 December 2012;

Received in revised form:

22 November 2015;

Accepted: 27 November 2015;

#### Keywords

FSH,  
LH,  
Adiponectin,  
Hormones.

### ABSTRACT

**Background:** The hypothalamic/pituitary/gonadal (HPG) axis is central to the mammalian reproductive system. Pulsatile release of GnRH from neurons in the hypothalamus stimulates the secretion of LH and FSH from gonadotropes in the anterior pituitary. It has long been recognized that reproductive function is closely associated with energy balance, and metabolic dysregulation is linked with reproductive abnormalities (Lu *et al.*, 2008). Compare the differences in levels of adiponectin, FSH, LH, testosterone and estradiol between the diabetic patients and control group and in diabetic patients according to the durations of disease for both males and females groups. Also study the relationship between adiponectin and hormones for both gender and for both diabetic groups and control also in diabetic patients according to the durations of disease. The statistical analysis of this study showed that patients with Type 2 diabetes of both males and females had significantly lower in adiponectin levels than control group ( $P < 0.05$ ), but this level of adiponectin significantly higher in females than males for both diabetic groups and control ( $p < 0.05$ ), while the levels of FSH and LH had significantly higher in diabetes group than control ( $p < 0.05$ ), also significantly higher in females than males for both diabetic groups and control ( $P < 0.05$ ). The result of hormonal analysis show there were no significant differences in estradiol and testosterone between diabetic groups and control ( $p > 0.05$ ). According to the durations of disease, the results show significant elevation in adiponectin level in third duration of disease for both males and females groups as compared with first and second duration ( $P < 0.004$ ), while the levels of FSH, LH, estradiol and testosterone show no significant differences among duration ( $P > 0.05$ ).

© 2015 Elixir All rights reserved.

### Introduction

Adiponectin was first identified in 1995, circulates at relatively high concentration of 2 to 30  $\mu\text{g/ml}$  in blood, accounting for up to 0.01% of total plasma protein in humans (Daimon *et al.*, 2003; Shimada *et al.*, 2004; Kadowaki *et al.*, 2006; Heidemann *et al.*, 2008).

Adiponectin is lower in men than women, possibly as a result of suppression by androgens. Moreover, women have higher proportions of high molecular weight adiponectin than men (Gavrila *et al.*, 2003; Snijder *et al.*, 2006).

Adiponectin exists in a wide range of multimer complexes in plasma and combines via its collagen domain to create 3 major oligomeric forms: a low-molecular weight (LMW) trimer, a middle-molecular weight (MMW) hexamer, and high-molecular weight (HMW) 12-18-mer adiponectin. Several observations support the hypothesis that HMW adiponectin is the more active form of the protein and has a more relevant role in insulin sensitivity and in protecting against diabetes (Shimada *et al.*, 2004; Kadowaki, *et al.*, 2006; Heidemann *et al.*, 2008).

Testosterone (T) regulates many important physiologic processes, including muscle and fat metabolism, sexual development and function, erythropoiesis, and bone metabolism

.Both T replacement therapy for hypogonadism and supraphysiologic administration of T are associated with increases in lean body mass, decreases in fat mass, and increases in muscle strength. T administration reduces overall fat mass and has been reported to decrease central adipose stores. In mice, castration increased adiponectin levels and insulin sensitivity, effects neutralized by the coadministration of T, whereas ovariectomy had no effect on female mice, implying a role for T in adiponectin regulation in male mice. Together, these studies suggest that T might negatively regulate adiponectin production or serum half-life (Page *et al.*, 2005; Hugo *et al.*, 2008).

In study of Tsujimura *et al.*, (2009) refer to inversely relation between adiponectin levels and testosterone in rodents and humans.

Insulin is a negative regulator of liver secretion of sex hormone binding globulin (SHBG). The concept has emerged that SHBG could be an interesting marker of insulin sensitivity in humans, and SHBG level has therefore been included as such among the biochemical markers for the risk of developing type 2 diabetes or cardiovascular diseases (Ducluzeau *et al.*, 2003).

An inhibitory effect of insulin on SHBG secretion also has been reported by Bonnet *et al.*, (2009), suggesting that increased

hyperinsulinemia could decrease SHBG concentration. A recent study showed that monosaccharide, including glucose or fructose, regulate human SHBG gene expression. The reduction of SHBG secretion in response to increased concentrations of glucose may provide a mechanism for the link between low-plasma levels of SHBG and insulin resistance. There is a specific receptor for adiponectin in the liver, suggesting the potential implication of adiponectin in the regulation of the secretion of SHBG.

#### Materials and Method

About five milliliters of venous blood were collected from each subject in the study. The blood was separated by centrifugation at (3000 rpm) for 15 min. The sera were stored frozen at (-20 °C) until assayed.

To determine the serum adiponectin, FSH, LH, estradiol and testosterone the quantitative sandwich enzyme immunoassay technique were used.

Moreover, the blood samples were taken in the morning exactly between 08:00 and 10:00 h, minimizing the effect of diurnal variation (Tenhola *et al.*, 2010).

#### Adiponectin / Principle of assay

A monoclonal antibody specific for the adiponectin globular domain has been pre-coated onto amicroplate. Standards and sample are pipette into the wells and any adiponectin present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked monoclonal antibody specific for the adiponectin globular domain is added to the wells. Following wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of adiponectin bound in the initial step. The color development is stopped and the intensity of the color is measured (R & D systems, Inc., Minneapolis, MN, USA).

#### Statistical Analysis:

Analysis were performed using the Statistical Package for Social Sciences (SPSS version 18.0). Hormonal data were analyzed with durations of disease and with age using Factorial experiment with completely randomized design with three factors, while analyzed between groups using Factorial experiment with completely randomized design with two factors. Data were represented as mean  $\pm$  SE. Bivariate correlations were performed using the Pearson correlation coefficient. P value ( $P < 0.05$ ) was considered statistically significant.

#### Result:

The results of present study show there were significant differences in adiponectin level and some hormones levels between the diabetic groups and control. The mean adiponectin concentration differ significantly between two groups. Patients with Type 2 diabetes of both male and female had significantly lower levels of adiponectin concentration than control group ( $(3.84 \pm 0.17)$  vs.  $(4.15 \pm 0.3)$  and  $(5.81 \pm 0.3)$  vs.  $(7.3 \pm 0.17)$  ( $\mu\text{g/ml}$ ) ( $P < 0.05$ ), while the levels of FSH and LH had significantly higher in diabetes group than control ( $P < 0.05$ ). Also the result of hormonal analysis show there were no significant differences in estradiol and testosterone levels between diabetic patients and control ( $P > 0.05$ ) as shown in Table(1).

Levels of adiponectin and hormones according to gender had significantly differences in diabetes mellitus. Serum adiponectin concentration was significantly higher in females than males for both control and diabetic groups ( $(5.81 \pm 0.17)$  vs.  $(3.84 \pm 0.17)$  ( $\mu\text{g/ml}$ ) and  $(7.3 \pm 0.3)$  vs.  $(4.15 \pm 0.3)$

( $\mu\text{g/ml}$ ) ( $P < 0.05$ ). The levels of FSH, LH and estradiol were significantly higher in females than males for both diabetic groups and control ( $P < 0.05$ ), whereas the testosterone concentration was significantly higher in males than females for both groups ( $(8.36 \pm 0.07)$  vs.  $(0.68 \pm 0.07)$  ( $\text{ng/ml}$ ) and  $(7.58 \pm 0.06)$  vs.  $(1.36 \pm 0.06)$  ( $\text{ng/ml}$ ) respectively ( $P < 0.05$ ) as shown in Table(1).

According to the durations of disease, the results show significant elevation in adiponectin level in third duration of disease for both males and females groups ( $4.28 \pm 0.31$ ) and  $(7.6 \pm 0.31)$  as compared with first and second duration ( $3.35 \pm 0.31$ ),  $(3.89 \pm 0.31)$  and  $(5.38 \pm 0.31)$ ,  $(4.44 \pm 0.31)$  respectively ( $P < 0.004$ ), while the levels of FSH, LH, estradiol and testosterone show no significant differences among duration ( $P > 0.05$ ). According to the gender, levels of adiponectin, FSH, LH, and estradiol were significantly higher in females than males ( $P < 0.05$ ), whereas levels of testosterone was significantly higher in males than females ( $P < 0.05$ ) as shown in Table (2).

Correlation analysis showed an inverse correlation between adiponectin and FSH in female diabetic patients ( $r = -0.35$ ,  $P = 0.03$ ). Also an inverse correlation between adiponectin and estradiol was found in females of control group, while the correlation of LH and testosterone with adiponectin appears no significant correlation for both groups and for both males and females as shown in Table (3).

According to the durations of disease, the study revealed in male diabetic patients positive correlation between adiponectin and FSH in first duration was found ( $r = 0.78$ ,  $P = 0.01$ ). In female diabetic patients an inverse correlation between adiponectin and FSH in third duration of female diabetic patients ( $r = -0.75$ ,  $P = 0.01$ ) and ( $r = -0.67$ ,  $P = 0.04$ ) respectively. The results appears no significant correlation between adiponectin with LH, estradiol and testosterone in both sex among duration as shown in Table (4).

#### Discussion

The result of present study show that the patients with Type 2 diabetes of whether male or female had significantly lower in adiponectin concentration than control group and the levels of adiponectin was higher in female than male for both groups (Table 1), this may be due to a number of factors, one of them was the diabetic patients had decreased high molecular weight (HMW) -to- total adiponectin ratio, and HMW adiponectin correlated better with glucose tolerance than total adiponectin also the HMW was acted the active form of this protein. Women have more HMW adiponectin than men, which may partly explain the differences that we have found between men and women (Snijder *et al.*, 2006).

Also decreased in adiponectin levels in diabetic patients may due to elevated plasma insulin in diabetic subjects in onset of diabetes and the insulin was down-regulated adiponectin mRNA expression and it has been found that the hyperinsulinemia associated with higher levels of adiponectin in Type 1 DM (Hotta *et al.*, 2000; Huerta, 2006; Habeeb *et al.*, 2012).

Testosterone (T) decrease adiponectin level by sequestering ARA70, a coactivator common to both the androgen receptor (AR) and peroxisome proliferator-activated receptor gamma 1 (PPAR $\gamma$ 1,2). The AR, and ARA70 are all expressed in human adipocytes, and ARA70 is upregulated during adipocyte differentiation, a PPAR $\gamma$ -mediated process.

**Table(1): Differences in levels of adiponectin and some hormones between Type 2diabetic patients and control and between gender**

Indices \ Groups	Control (Means± S.E.)		Diabetes groups (Means± S.E.)		P value of gender	P value of group
	Male	Female	Male	Female		
Adiponectin(µg/ml)	4.15 ± 0.3	7.3 ± 0.3	3.84 ± 0.17	5.81 ± 0.17	0.00*	0.04*
FSH(mIU/ml)	8.78 ± 0.3	31.6 ± 0.3	28.01 ± 4.79	38.62 ± 4.79	0.008*	0.03*
LH( mIU /ml)	4.63 ± 0.36	12.53 ± 0.36	6.94 ± 0.36	18.23 ± 0.36	0.00*	0.04*
Estradiol(pg/ml)	21.53 ± 4.95	32.13 ± 4.95	21.07 ± 4.59	35.02 ± 4.59	0.05*	0.85
Testosterone (ng/ml)	8.36 ± 0.07	0.68 ± 0.07	7.58 ± 0.06	1.36 ± 0.06	0.00*	0.27

P value is significant ≤ 0 .05 level. S.E :Standard error

**Table(2): Comparison of adiponectin levels and some hormones of Type 2diabetic patients among durations of disease and between gender**

Indices	Diabetes groups (Means± S.E.)						P value of gender	P value of duration
	0-5		>5-10		>10			
	Male	Female	Male	Female	Male	Female		
Adiponectin (µg/ml)	3.35 ± 0.31	5.38 ± 0.31	3.89 ± 0.31	4.44 ± 0.31	4.28 ± 0.31	7.6 ± 0.31	0.002*	0.004*
FSH(mIU /ml)	18.16 ± 0.34	36.18 ± 0.34	29.8 ± 0.34	41.31 ± 0.34	36.06 ± 0.34	38.39 ± 0.34	0.008*	0.055
LH( mIU l/ml)	8.52 ± 0.31	15.55 ± 0.31	5.56 ± 0.31	22.95 ± 0.31	6.72 ± 0.31	16.18 ± 0.31	0.00*	0.17
Estradiol (pg/ml)	21.17 ± 4.17	33.98 ± 4.17	20.98 ± 4.17	38.71 ± 4.17	21.07 ± 4.17	32.38 ± 4.17	0.02*	0.97
Testosterone (ng/ml)	8.48 ± 0.09	1.58 ± 0.09	6.00 ± 0.09	1.00 ± 0.09	8.25 ± 0.09	1.51 ± 0.09	0.00*	0.22

P value is significant ≤ 0 .05 level. S.E :Standard error

**Table (3): Correlation analysis between adiponectin and some hormones of Type 2diabetic patients and control.**

Indices \ Groups	Adiponectin(µg/ml) Control groups				Adiponectin(µg/ml) Diabetes groups			
	Male		Female		Male		Female	
	r	P value	r	P value	r	P value	r	P value
FSH( mIU /ml)	0.35	0.34	-0.42	0.24	-0.01	0.94	-0.35*	0.03
LH( mIU /ml)	0.25	0.5	-0.41	0.26	0.01	0.92	-0.19	0.34
Estradiol(pg/ml)	-0.67	0.54	-0.25*	0.05	0.06	0.74	-0.14	0.47
Testosterone (ng/ml)	0.59	0.09	0.5	0.16	-0.03	0.88	0.17	0.37

Correlation coefficient (r)

\*. Correlation is significant ≤ 0.05 level (2-tailed).

**Table (4): The relationship between adiponectin and hormones of diabetic patients Type 2 according to the durations of disease**

Indices	Adiponectin(µg/ml) Diabetes groups											
	0-5				>5-10				>10			
	Male		Female		Male		Female		Male		Female	
	r	P	r	P	r	P	r	P	r	P	r	P
FSH ( mIU /ml)	0.78*	0.01	-0.4	0.28	0.15	0.68	-0.11	0.77	-0.26	0.48	-0.67*	0.04
LH( mIU /ml)	0.56	0.11	-0.14	0.7	0.25	0.51	0.02	0.95	0.15	0.68	-0.1	0.79
Estradiol (pg/ml)	-0.15	0.69	-0.25	0.5	-0.07	0.84	-0.23	0.55	0.3	0.42	0.02	0.95
Testosterone (ng/ml)	-0.19	0.6	0.08	0.83	0.64	0.06	-0.28	0.45	-0.35	0.35	0.17	0.65

Correlation coefficient (r)

\*. Correlation is significant ≤ 0.05 level (2-tailed).

In this model, interaction of the AR with T might compete with PPAR $\gamma$  for ARA70, resulting in reduced expression of PPAR $\gamma$ -regulated genes such as adiponectin (Page *et al.*,2005).

Mankowska *et al.*,(2008) indicate to human plasma adiponectin concentration is associated with sex and is significantly higher in woman than in men. This sexual dimorphism develop during pubertal development in relation to serum androgen.

The result of this study agree with the study of Bai *et al.*,(2011) that found the patients with Type 2 diabetes have lower adiponectin serum concentration than healthy individuals.

In diabetic patients and according to the duration of disease the results show significant elevation in adiponectin levels in third duration of disease for both males and females groups as compared with first and second duration(Table 2), this differences belong to that adiponectin is lowest in the presence of impaired glucose regulation and early diabetes, whereas long diabetes duration is associated with a significant increase in circulating adiponectin, changes in insulin concentration with increasing duration of diabetes could be one mechanism by which serum adiponectin is influenced by diabetes duration (Looker *et al.*,2004 ; Eynatten *et al.*,2009).

Also study show the patients with Type 2 diabetes had revealed defect in hypothalamic than pituitary axis. Levels of FSH and LH significantly higher in diabetes group than control (P<0.05), while the levels of estradiol and testosterone show no significant differences between groups (Table 4),this is because that insulin is known to facilitate gonadotropin-releasing hormone (GnRH) secretion by hypothalamic neurons(Dhindsa *et al.*,2011).

In study by Ermetici *et al.*,(2009) indicated to the insulin-like factor 3 (INSL3), a member of the insulin-relaxin superfamily of peptide hormones, has been used as a specific marker of Leydig cell differentiation and function, since it appears more sensitive than testosterone itself in evaluating function . The global impairment of Leydig cell function in T2DM is confirmed by the finding of reduced circulating levels of INSL3, a novel peptide hormone mainly derived from Leydig cells, which have been indicated as an absolute measure of either quality or number of the Leydig cells, independently from gonadotropin stimulation. The higher LH levels in diabetic patients than in controls might suggest that when few or poor-quality Leydig cells are present, more LH is required to achieve normal circulating testosterone levels. Since the presence of the INSL3 receptor has been demonstrated at pituitary level, a possible negative feedback of INSL3 has also been hypothesized.

Also may be because that leydig cells and follicle cells become resistant to gonadotropin hormone as a result higher levels of FSH and LH with low normal range of estradiol and testosterone in diabetic patients.

The result show no significant differences in testosterone concentration between control and diabetic patients whereas the average testosterone concentration was significantly higher in males for both groups than in females and in diabetic patients among duration(Table 1 and 2),this result agreement with study of Bia *et al.*,(2011) that found there were no significant differences in mean testosterone concentration between the diabetic patients Type 2 and control group , also found that in both patients and control group average testosterone concentration was higher in males than females.

These result also show no significant differences between the diabetic patients Type 2 and control group in estradiol concentration which supported by study of AL-Saadi,(2005) that found no significant differences in the levels of estradiol hormone between women with Type 2 diabetes and healthy women in postmenopausal age.

According to the gender ,levels of FSH ,LH and estradiol were significant higher in females than males for both control and diabetic group and in diabetic group among duration of disease(Table 1 and 2). Bonnet *et al.*, (2009) refer that sex hormone-binding globulin levels(SHBG) was higher in females than males for both control and diabetic groups which made the percentage of free estradiol and the negative feedback mechanism in female was highly than in males which may cause the levels of FSH and LH became highly in females than males.

In diabetic patients according to the duration of disease, levels of FSH, LH, estradiol and testosterone show no significant differences among duration (Table 2) .Higher levels of FSH, LH ,estradiol and testosterone in first duration in males and in second duration in females causes lower levels from adiponectin in this duration but this changes not reach to the significant value. Changes in insulin concentration with increasing duration of diabetes and because the insulin is known to facilitate gonadotropin-releasing hormone (GnRH) secretion by hypothalamic neurons (Looker *et al.*,2004 ; Dhindsa *et al.*,2011). An inverse correlation between adiponectin and FSH in female diabetic patients(Table 3) also in third duration of female diabetic patients(Table 4) ,while the correlation of LH with adiponectin appears no significant correlation for both groups and for both males and females (Table 3) and in diabetic patients among duration(Table 4) ,this is because that adiponectin decreases basal and GnRH-stimulated LH secretion via activation of AMPK. A decrease in cellular ATP activates AMPK that, in turn, inhibits energy-requiring processes and stimulates ATP production by increasing glucose uptake and fatty acid oxidation .Trafficking and fusion of secretory vesicles is ATP dependent, so may be directly inhibited by AMPK. Alternatively, the calcium increases essential for stimulating secretion may be blocked (Lu *et al.*, 2008).

Adiponectin is present in follicular fluid and induces cyclooxygenase 2,prostaglandin E synthase, vascular endothelial growth factor, and steroidogenic acute regulatory protein mRNAs(Lu *et al.*, 2008),this may be result that adiponectin affected in FSH levels more than LH, which may be explain this inverse correlation between adiponectin and FSH also with LH level but in this study not reach to significant levels.

An inverse correlation between adiponectin and estradiol was found in females of control group(Table 3), because the estrogen may be involved in adipose tissue disposition and regulation preadipocyte proliferating and differentiation ,thus, could reduce adiponectin (Tworoger *et al.*,2007).

This result supported by result of (Gavrila *et al.*, 2003) that found adiponectin has been inversely associated with estrogen levels in healthy women. Despite the negative association between estradiol and adiponectin, it has been reported that women have higher adiponectin levels compared with men, suggesting that in addition to estrogens, other gender-dependent factors, such as body fat distribution or androgen may be of relevance

## References

Al-Saadi,H.K.Z.(2005).Physiological and biochemical changes of some adrenocortico and pituitary hormones in patients with

non-insulin dependent diabetes mellitus .Ph.D. Thesis, College of Science, University of Al-Mustansiriyah.

**Bai,J.**;Liu, Y.;Niu, G-F.;Bai, L-X.;Xu, X-Y.; Zhang,G-Z. and Wang,L-X.(2011). Relationship between adiponectin and testosterone in patients with type 2 diabetes. *Biochemia Medica*,21(1):65-70.

**Bonnet,F.**; Balkau,B.; Malecot,J.M.; Picard,P.; Lange,C.; Fumeron,F.; Aubert, R.; Raverot, V.; Dechaud,H.; Tichet,J.; Lecomte,P. and Pugeat, M.(2009). Sex hormone -binding globulin predicts the incidence of hyperglycemia in women: interactions with adiponectin levels. *European Journal of Endocrinology* ,161:81–85.

**Daimon,M.**; Oizumi,T.; Saiton,T.; Kameda,W.; Hirata,A.; Yamaguchi, H.; Ohnuma, H.; Igarashi, M.; Tominage,M. and Kato,T.(2003).Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population. *Diabetes Care*, 26:2015-2020.

**Dhindsa,S.**; Furlanetto,R.; Vora,M.; Ghanim,H.; Chaudhuri,A.; and Dandona, P.(2011). Low estradiol concentrations in men with subnormal testosterone concentrations and Type 2 diabetes.*Diabetes Care*,34:1854–1859.

**Ducluzeau,P-H.**; Cousin,P.; Malvoisin,E.; Bornet,H.;Vidal,H.; Laville,M. and Pugeat,M. (2003). Glucose-to-insulin ratio rather than sex hormone- binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. *The Journal of Clinical Endocrinology and Metabolism* , 88(8):3626 –3631.

**Ermetici,F.**; Donadio,F.; Iorio,L.; Malavazos,A.E.; Dolci,A.;Peverelli,E.; Barbieri,A.M.; Morricone,L.; Chiodini,I.; Arosio,M.; Lania, A.; Beck-Peccoz, P.; Ambrosi,B. and Corbetta,S.(2009).Peripheral insulin-like factor 3 concentrations are reduced in men with type 2 diabetes mellitus: effect of glycemic control and visceral adiposity on leydig cell function.*European Journal of Endocrinology* ,161:853–859.

**Eynatten,M.**; Liu,D.; Hock,C.; Oikonomou,D.; Baumann,M.; Allolio,B.; Korosoglou,G.; Morcos,M.; Campean,V.; Amann,K.;Lutz, J. ; Heemann,U.; Nawroth,P.P.; Bierhaus, A. and Humpert ,P.M. (2009). Urinary adiponectin excretion. A novel marker for vascular damage in type 2diabetes. *Diabetes*,58:2093–2099.

**Gavrila,A.**; Chan ,J.L.; Yiannakouris, N.; Kontogianni, M.; Miller,L.C.; Orlova ,C. and Mantzoros, C.S.(2003). Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans:Cross-sectional and interventional studies. *The Journal of Clinical Endocrinology &Metabolism* ,88(10):4823– 4831.

**Habeeb,N.M.M.**; Youssef,O.I.; Saab,A.A.R. and EL-Hadidi,E.S.(2012). Adiponectin as a marker of complications in Type I diabetes. *Indian Pedia Trics*,49:277-280.

**Heidemann,C.**;Sun,Q.;Dam,R.M.V.;Meigs,J.B.;Zhang,C.;Tworoger,S.S.;Mantzoros,C.S.and Hu, F.B. (2008).Total and high-molecular- weight adiponectin and resisten in relation to the risk for type 2 diabetes in wemen.*Annals of Internal Medicine* ,149(5):307-316.

**Hotta,k.**;Funahashi,T.;Arita,Y.;Takahashi,M.;Matsuda,M.;Okamoto,Y.;Iwahashi ,H.;Kuriyama, H.; Ouchi,N.; Maeda,K.;Nishida,M.; Kihara, S.;Sakai,N.; Nakajima, T.;Hasegawa, K.;

Muraguchi,M.; Ohmoto,Y.; Nakamura,T.; Yamashita,S.; Hanafusa,T. and Matsuzawa, Y. (2000) .Plasma concentrations of a novel adipose- specific protein, adiponectin, in Type 2 diabetic patients. *Arterioscler ThrombVasc Biol.*,20:1595-1599.

**Hugo,E.R.**;Brandebourg,T.D.;Woo,J.G.;Loftus,J.;Alexander,J.W . and Ben-Jonathan, N.(2008).Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes. *Environ Health Perspect* , 116: 1642–1647.

**Huerta,M.G.**(2006).Adiponectin and leptin:Potential tools in the differential diagnosis of pediatric diabetes?.*Rev Endocr Metab Disord*,7:187-196.

**Kadowaki,T.**; Yamauchi,T.; Kubota,N.; Hara,K.; Ueki,K. and Tobe,K. (2006). Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. *J. Clin.Invest.*,116:1784–1792.

**Looker,H.C.**; Krakoff,J.; Funahashi,T.; Matsuzawa,Y.; Tanaka,S.; Nelson, R.G.; Knowler, W.C.;Lindsay,R.S. and Hanson,R.L. (2004). Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with Type 2 diabetes. *J. Clin.Endocrinol.Metab.* ,89: 4010-4017.

**Lu,M.**; Tang,Q.; Olefsky,J.M.; Mellon,P.L. and Webster,N.J.G.(2008). Adiponectin activates adenosine monophosphate-activated protein kinase and decreases luteinizing hormone secretion in LβT2 gonadotropes. *Molecular Endocrinology* , 22 (3):760–771.

**Mankowska,A.**; Nowak,L. and Sypniewska,G.(2008). Adiponectin and metabolic syndrome in women at menopause. *eJIFCC – The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine*,19(4):1-12.

**Page,S.T.**; Herbst,K.L.; Amory,J.K.; Coviello,A.D.; Anawalt,B.D.; Matsumoto, A.M. and Bremner, W.J. (2005). Testosterone administration suppresses adiponectin levels in men. *Journal of Andrology* ,26:85–92.

**Shimada,K.**; Miyazaki,T. and Daida,H.(2004). Adiponectin and atherosclerotic disease. *Clinica Chimica Acta* ,344 :1–12.

**Snijder,M.B.**; Heine, R.J.; Seidell, J.C.;Bouter, L.M.; Stehouwer, C.D. A; Nijpels, G.; Funahashi, T.; Tsuzawa, Y.; Shimomura, I. and Dekker,J.M . (2006).Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women. *Diabetes Care*, 29:2498–2503.

**Tenhola,S.**; Todorova,B.; Jaaskelainen,J.; Ajanne,O.; Raivio,T. and Voutilainen, R. (2010). Serum glucocorticoids and adiponectin associate with insulin resistance in children born small for gestational age. *European Journal of Endocrinology* , 162 :551–557.

**Tsujimura,A.**; Takada,S.; Matsuoka,Y.; Nakayama,J.; Takao,T.; Miyagawa ,Y.; Sonoda,M.; Nishizawa, H.; Iwahashi,H.; Funahashi, T.;Nonomura,N. and Okuyama,A.(2009). Adiponectin and testosterone in patients with symptoms of late-onset hypogonadism: Is there a link?. *International Journal of Urology* ,16: 830–835.

**Tworoger,S.S.**; Mantzoros,C. and Hankinson, S.E. (2007). Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levels. *Obesity* ,15(9):2217–2224.